Whistleblower Claims GlaxoSmithKline Lies to FDA, Federal Government About Zantac Safety Claims

Whistleblower Claims GlaxoSmithKline Lied to FDA, Federal Government About Zantac Safety Claims

A whistleblower has come out with allegations that GlaxoSmithKline (GSK) deceived the public about the safety of Zantac, a popular heartburn medicine.

Read Full Article

GSK Settles California Lawsuit Over Zantac Cancer Allegations, Avoids Trial

GSK resolves California lawsuit over Zantac cancer claims in a confidential settlement, avoiding trial amid ongoing legal battles.

Read Full Article

GSK Got Positive Recommendation for Its Gene Therapy for Bubble Boy Disease, Expecting Approval Soon

A gene therapy for Bubble Boy Disease has received positive evaluation from European regulatory panel, paving a way for official approval. Currently, there’s no gene therapy for the disease, and the therapy would enhance patient’s success in survival and even recovery.

Read Full Article

Doubts grow over GlaxoSmithKline's $6 billion capital return plan

GlaxoSmithKline (GSK.L) may ditch a plan to return 4 billion pounds ($6.1 billion) to investors, some analysts believe, as the drugmaker prepares to set out its vision for the reshaped group and a new chairman takes the helm.

Read Full Article

GSK raises $853 million by halving stake in South African drugmaker

GlaxoSmithKline (GSK.L) has taken profits in Aspen Pharmacare (APNJ.J) by selling half its stake in the South African drugmaker for $853 million, following a long investment in the firm.

Read Full Article

Trial finds GSK Ebola shot is safe and provokes immune response

First results from a human trial of an Ebola vaccine from GlaxoSmithKline show it is safe and generates an immune response, scientists said on Wednesday, but larger trials are needed to see if it protects and if a booster is needed.

Read Full Article

GSK's nicotine patches and gum feel the heat from e-cigarettes

GlaxoSmithKline is feeling the heat from the rapid growth in electronic cigarettes, with enthusiasm for the nicotine delivery devices dampening sales of the British drugmaker's patches and gum, its chief executive said.

Read Full Article

Galapagos loses partner on inflammatory bowel drug

Belgian biotech group Galapagos said on Tuesday that its research partner Janssen Pharmaceutica, a unit of Johnson & Johnson, had pulled out of a program to develop a new drug to treat bowel disease.

Read Full Article

GlaxoSmithKline drops plan to sell off older drugs business

GlaxoSmithKline said on Thursday it had decided not to sell a portfolio of older drugs marketed in North America and Europe after considering offers from potential buyers.

Read Full Article

GSK cuts U.S. sales and research jobs as market gets tougher

GlaxoSmithKline (GSK.L) said on Wednesday it would shed "several hundred" U.S. commercial jobs and a similar number of research positions as it restructures operations in its biggest market, where drug sales are flagging.

Read Full Article

Drugmakers may need indemnity for fast-tracked Ebola vaccines

Drugmakers are looking for some kind of indemnity from governments or multilateral agencies against possible losses or claims arising from the widespread emergency use of new Ebola vaccines in Africa.

Read Full Article

Plant-based vaccines challenge big pharma for $3 billion flu market

Two tiny companies are preparing to challenge some of the world's largest drug makers in the battle for dominance in the $3 billion global market for influenza vaccines, armed with little more than tiny tobacco plants.

Read Full Article

Vernalis and Asahi Kasei Pharma Achieve Milestone

Vernalis is pleased to announce the achievement of the first milestone in its research collaboration with Asahi Kasei Pharma (AKP).

Read Full Article

GSK sells thrombosis drugs to Aspen

GSK had agreed to put its thromobosis drugs on sale to Aspen Pharmacare with proceeds to be used for general corporate purposes.

Read Full Article

First GSK, now China focuses investigations on Sanofi

Xinhua reported that French drugmaker Sanofi had become the focus of bribery investigations by Chinese authorities.

Read Full Article
1 2

Subscribe to VCpost newsletter

Sign up for our Deals of the Day newsletter.
We will not spam you!

Real Time Analytics